The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Challenges of in vivo gene editing for diseases of the hematopoietic system
Agnieszka Czechowicz, MD, PhD, Stanford University, Stanford, CA, outlines the obstacles to in vivo gene editing for diseases of the hematopoietic system, which mainly include concerns about the toxicity of this procedure. Currently, patients are treated with ex vivo gene editing and allogeneic cell therapies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
